Trial watch: STING agonists in cancer therapy

Trial watch: STING agonists in cancer therapy

Stimulator of interferon response cGAMP interactor 1 (STING1, best known as STING) is an endoplasmic reticulum-sessile protein that serves as a signaling hub, receiving input from several pattern recognition receptors, most of which sense ectopic DNA species in the cytosol. In particular, STING ensu...

Full description

Bibliographic Details
Main Authors:	Julie Le Naour, Laurence Zitvogel, Lorenzo Galluzzi, Erika Vacchelli, Guido Kroemer
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2020-01-01
Series:	OncoImmunology
Subjects:	cdk4/cdk6 inhibitors cgas exosomes dna damage response immune checkpoint blockers parp1 type i interferon
Online Access:	http://dx.doi.org/10.1080/2162402X.2020.1777624

Similar Items

Trial watch: TLR3 agonists in cancer therapy
by: Julie Le Naour, et al.
Published: (2020-01-01)

Trial watch: IDO inhibitors in cancer therapy
by: Julie Le Naour, et al.
Published: (2020-01-01)

Trial watch: Toll-like receptor ligands in cancer therapy
by: Julie Le Naour, et al.
Published: (2023-12-01)

CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
by: Mattia Garutti, et al.
Published: (2021-05-01)

Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
by: Abhishek D. Garg, et al.
Published: (2017-12-01)

Stable CDK12 Knock-Out Ovarian Cancer Cells Do Not Show Increased Sensitivity to Cisplatin and PARP Inhibitor Treatment
by: Rosaria Chilà, et al.
Published: (2022-07-01)

Trial Watch: Adoptively transferred cells for anticancer immunotherapy
by: Carole Fournier, et al.
Published: (2017-11-01)

Does the Rechallenge with Another CDK 4/6 Inhibitor in Breast Cancer Work? A Case Report and Literature Review
by: Ioana-Miruna Stanciu, et al.
Published: (2023-04-01)

Expanded Indications of Molecular-Targeted Drugs in Perioperative Therapy of Breast Cancer
by: Eiichiro Noguchi, et al.
Published: (2024-06-01)

Stressing Mitosis to Death
by: Andrew eBurgess, et al.
Published: (2014-06-01)

Trial watch: Dendritic cell-based anticancer immunotherapy
by: Abhishek D. Garg, et al.
Published: (2017-07-01)

A mitochondrial checkpoint to adaptive anticancer immunity
by: Oliver Kepp, et al.
Published: (2023-12-01)

Dual Inhibition of CDK4/6 and CDK7 Suppresses Triple‐Negative Breast Cancer Progression via Epigenetic Modulation of SREBP1‐Regulated Cholesterol Metabolism
by: Yilan Yang, et al.
Published: (2025-02-01)

Identification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer
by: Shifeng Yang, et al.
Published: (2022-04-01)

Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b study
by: Sara M. Tolaney, et al.
Published: (2025-03-01)

Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer
by: Navid Sobhani, et al.
Published: (2021-02-01)

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study
by: Sara M. Tolaney, et al.
Published: (2022-02-01)

CDK6 Immunophenotype Implicates Potential Therapeutic Application of CDK4/6 Inhibitors in Urothelial Carcinoma
by: Ran Sun, et al.
Published: (2022-04-01)

Sensitizing HR-proficient cancers to PARP inhibitors
by: Elgene Lim, et al.
Published: (2017-11-01)

Trial watch: dendritic cell vaccination for cancer immunotherapy
by: Jenny Sprooten, et al.
Published: (2019-11-01)

Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment
by: Ni Made Pitri Susanti, et al.
Published: (2021-07-01)

Cell Cycle-Related lncRNAs as Innovative Targets to Advance Cancer Management
by: Liang XR, et al.
Published: (2023-07-01)

Novel CDKs inhibitors for the treatment of solid tumour by simultaneously regulating the cell cycle and transcription control
by: Xin Wang, et al.
Published: (2020-01-01)

Cell cycle regulation and anticancer drug discovery
by: Jingwen Bai, et al.
Published: (2017-08-01)

NK cells beat T cells at early breast cancer control
by: Aitziber Buque, et al.
Published: (2020-01-01)

Targeting cell cycle regulators in hematologic malignancies
by: Eiman eAleem, et al.
Published: (2015-04-01)

Recent developments in the role of DNA damage response and understanding its implications for new therapeutic approaches in Alzheimer's disease
by: Rajesh Ranganathan, et al.
Published: (2023-01-01)

Upregulated PARP1 confers breast cancer resistance to CDK4/6 inhibitors via YB-1 phosphorylation
by: Chuntao Quan, et al.
Published: (2023-11-01)

Assessment of Postvaccination Neutralizing Antibodies Response against SARS-CoV-2 in Cancer Patients under Treatment with Targeted Agents
by: Flora Zagouri, et al.
Published: (2022-09-01)

A Journey through Time on the Discovery of Cell Cycle Regulation
by: Rustem Uzbekov, et al.
Published: (2022-02-01)

CDK4/6 inhibitors promote PARP1 degradation and synergize with PARP inhibitors in non-small cell lung cancer
by: Carlos M Roggero, et al.
Published: (2025-02-01)

AGA induces sub-G1 cell cycle arrest and apoptosis in human colon cancer cells through p53-independent/p53-dependent pathway
by: Bou-Yue Peng, et al.
Published: (2023-01-01)

Characterizing CDK8/19 Inhibitors through a NFκB-Dependent Cell-Based Assay
by: Jing Li, et al.
Published: (2019-10-01)

Insights into the structural and functional activities of forgotten Kinases: PCTAIREs CDKs
by: Javad Karimbayli, et al.
Published: (2024-06-01)

SAMHD1 Phosphorylation Coordinates the Anti-HIV-1 Response by Diverse Interferons and Tyrosine Kinase Inhibition
by: Matthew A. Szaniawski, et al.
Published: (2018-07-01)

The Inhibition of CDK8/19 Mediator Kinases Prevents the Development of Resistance to EGFR-Targeting Drugs
by: Amanda C. Sharko, et al.
Published: (2021-01-01)

CDK5: an oncogene or an anti-oncogene: location location location
by: Kumar Nikhil, et al.
Published: (2023-11-01)

Targeted and cytotoxic inhibitors used in the treatment of breast cancer
by: Robert Roskoski Jr.
Published: (2024-12-01)

Compartmentalized control of Cdk1 drives mitotic spindle assembly
by: Angela Flavia Serpico, et al.
Published: (2022-01-01)

CDK4/6 inhibitors: a novel strategy for tumor radiosensitization
by: Yilan Yang, et al.
Published: (2020-09-01)